Brenner et al., 1974 - Google Patents

Intramuscular administration of 15 (S)-15-methyl-prostaglandin E2-methyl ester for induction of abortion

Brenner et al., 1974

Document ID
14654949947702387525
Author
Brenner W
Dingfelder J
Staurovsky L
Kumarasamy T
Grimes D
Publication year
Publication venue
American Journal of Obstetrics and Gynecology

External Links

Snippet

To test the practicability of administering 15 (S)-15-methyl-prostaglandin E 2-methyl ester [15 (S)-ME-PGE 2] intramuscularly for the induction of midtrimester abortion, 20 subjects were treated with 5 μg of 15 (S)-ME-PGE 2 every 4 hours. Sixty-five per cent aborted within …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins

Similar Documents

Publication Publication Date Title
Brenner et al. Intramuscular administration of 15 (S)-15-methyl-prostaglandin E2-methyl ester for induction of abortion
Karim et al. The use of prostaglandin E2 for therapeutic abortion
Embrey et al. Extra amniotic prostaglandins in the management of intrauterine fetal death, anencephaly and hydatidiform mole
Lauersen et al. Midtrimester abortion induced by serial intramuscular injections of 15 (S)-15-methyl-prostaglandin F2α
Ingemanson Legal abortion by extra-amniotic instillation of Rivanol in combination with rubber catheter insertion into the uterus after the twelfth week of pregnancy
Brenner et al. Intra-amniotic administration of prostaglandin F2α to induce therapeutic abortion: Efficacy and tolerance of two dosage schedules
Lauersen et al. Midtrimester abortion induced with a single intra-amniotic instillation of prostaglandin F2α
LAUERSEN et al. Effect of oxytocic agents on blood loss during first trimester suction curettage
Hern et al. Multiple laminaria treatment in early midtrimester outpatient suction abortion: a preliminary report
Beernink et al. Pituitary insufficiency associated with pregnancy, panhypopituitarism, and diabetes insipidus
Granström et al. Intravenous Infusion of 15 Methyl-Prostaglandin F2α (Prostinfenem®) in Women with Heavy Post-Partum Hemorrhage
Pritchard Hemostatic defects in pregnancy
Corson et al. Intra-amniotic prostaglandin F2α to induce midtrimester abortion
Ölund et al. Comparison of extra‐amniotic instillation of rivanol and pgf2α either separately or in combination followed by oxytocin for second trimester abortion
Ballard et al. Four years' experience with mid-trimester abortion by amnioinfusion
Gustavii Intra-amniotic and extra-amniotic injection of sodium chloride solution: amniotic fluid salinity and abortifacient effect
Lauersen Investigation of prostaglandins for abortion
Anderson et al. The induction of therapeutic abortion using intravenous prostaglandin F2α
Paz et al. Second trimester abortion by laminaria followed by vaginal misoprostol or intrauterine prostaglandin F2α: a randomized trial
Morewood Therapeutic abortion employing the synergistic action of extra‐amniotic prostaglandin E2 and an intravenous infusion of oxytocin
DOUGLAS et al. The immunologic role of the placenta
Ylikorkala et al. Induction of abortion with intra-amniotic or intra-muscular 15 (S)-15-methyl-prostaglandin F2α
Dillon et al. The efficacy of intramuscular 15 methyl prostaglandin E2 in second-trimester abortion: Coagulation and hormonal aspects
Kochenour et al. Midtrimester abortion produced by intra-amniotic prostaglandin F2α augmented with intravenous oxytoxin
Gardo et al. Induction of second trimester abortion by intraamniotic instillation of Rivanol (ethacridine) combined with oxytocin infusion